GlassScriptPhysician profile
Mary Tanner
NPI 1265212104
$4,588.75
in general payments reported to CMS, 2019-2025
23 companies · $2,121 in 2025
The $2,121 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $151 · 2024: $2,316 · 2025: $2,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,289 · Education: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,288.78 |
| Education | $299.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $692.31 | 2023-2025 | Ilumya |
| Novartis Pharmaceuticals Corporation | $630.96 | 2024-2025 | |
| Genzyme Corporation | $480.87 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $430.93 | 2024 | Sotyktu |
| Dermavant Sciences, INC. | $368.09 | 2024 | Vtama |
| Abbvie INC. | $337.73 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $286.95 | 2024-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $251.40 | 2024-2025 | Zoryve |
| Ucb, INC. | $204.03 | 2025 | Bimzelx |
| Incyte Corporation | $160.53 | 2024-2025 | Opzelura, Opzelura |
| Janssen Biotech, INC. | $159.34 | 2024-2025 | Tremfya |
| Janssen Scientific Affairs, LLC | $121.41 | 2025 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $115.65 | 2024 | Siliq, Duobrii, Cabtreo |
| Botanix Sb INC | $59.46 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.98 | 2023-2025 | Spevigo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $50.47 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Convatec INC. | $37.89 | 2023-2024 | |
| Pfizer INC. | $37.29 | 2024-2025 | |
| Galderma Laboratories, L.P. | $32.89 | 2025 | Nemluvio |
| Fresenius Kabi USA, LLC | $27.00 | 2024 | Idacio |
| Organon LLC | $20.66 | 2025 | |
| Biofrontera INC. | $17.17 | 2025 | |
| Mayne Pharma Commercial LLC | $8.74 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Tanner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.